Breaking News, Financial News

Financial Report: Amgen 3Q

Sales in the U.S. were flat at $2.9 billion in the quarter and sales included a $64 million unfavorable impact due to U.S. Health Care Reform.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Amgen 3Q 3Q Revenues: $3.8 billion (+1%) 3Q Earnings: $1.2 billion (-11%) YTD Revenues: $11.2 billion (+3%) YTD Earnings: $3.6 billion (-2%) Comments: Sales in the U.S. were flat at $2.9 billion in the quarter and sales included a $64 million unfavorable impact due to U.S. Health Care Reform. International sales were up 2% to $838 million. Foreign exchange rates negatively impacted sales in the quarter by $16 million. Worldwide sales of Aranesp were down 9% to $623 million due to ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters